James Dondero - Mar 16, 2023 Form 3 Insider Report for Paratek Pharmaceuticals, Inc. (PRTK)

Role
10%+ Owner
Signature
/s/ James D. Dondero
Stock symbol
PRTK
Transactions as of
Mar 16, 2023
Transactions value $
$0
Form type
3
Date filed
3/29/2023, 04:30 PM
Previous filing
Mar 9, 2023
Next filing
Mar 29, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PRTK Common Stock 1.9M Mar 16, 2023 See Footnote F1
holding PRTK Common Stock 50K Mar 16, 2023 See Footnote F2
holding PRTK Common Stock 2.89M Mar 16, 2023 See Footnote F3
holding PRTK Common Stock 1.07M Mar 16, 2023 See Footnote F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1,631,250 shares are held by Highland Global Allocation Fund, 64,770 shares are held by NexPoint Climate Tech Fund and 203,750 shares are held by NexPoint Event Driven Fund. These entities are managed by NexPoint Asset Management, L.P. ("NexPoint Asset Management"). Mr. Dondero is the sole stockholder and director of Strand Advisors XVI, Inc., NexPoint Asset Management's general partner, and may be deemed to be an indirect beneficial owner of securities held by NexPoint Asset Management. Mr. Dondero disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F2 50,000 shares are held by NexPoint Real Estate Opportunities Fund which is wholly owned by NexPoint Diversified Real Estate Trust Operating Partnership, L.P., which is wholly owned by NexPoint Diversified Real Estate Trust ("NXDT"). NXDT is advised indirectly by NexPoint Advisors, L.P. ("NP"). Mr. Dondero is the sole member of NP's general partner, and may be deemed to be an indirect beneficial owner of securities held by NP. Mr. Dondero disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
F3 2,889,060 shares are held by a trust of which Mr. Dondero is the beneficiary. Mr. Dondero disclaims beneficial ownership of the shares held by the trust except to the extent of his pecuniary interest therein.
F4 Mr. Dondero owns 75% of PCMG Trading Partners XXIII, L.P. ("PCMG") and PCMG owns 99% of Drugcrafters. These entities are ultimately controlled by Mr. Dondero. Mr. Dondero may be deemed to be an indirect beneficial owner of the shares held by Drugcrafters. Mr. Dondero disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Remarks:

No securities are beneficially owned.